Pharmaceutical Continuous Manufacturing Market Report 2026

Pharmaceutical Continuous Manufacturing Market Overview

• Pharmaceutical Continuous Manufacturing market size has reached to $2.69 billion in 2025 • Expected to grow to $4.58 billion in 2030 at a compound annual growth rate (CAGR) of 11.4% • Growth Driver: Rise In Industrial Automation To Drive Market Growth • Market Trend: Innovative Continuous Manufacturing Line Transforming The Market • Western Europe was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Pharmaceutical Continuous Manufacturing Market?

Pharmaceutical continuous manufacturing (PCM) is a process of producing pharmaceutical goods from start to finish on a single, straight production line. It is utilized to manufacture active pharmaceutical components by flow chemical transformations and multistep syntheses that can operate for a longer length of time, potentially reducing medicine shortages. The main types of pharmaceutical continuous manufacturing products are integrated continuous systems, controls and software, and semi-continuous systems. The Integrated Continuous System (ICS) is a way of producing pharmaceutical items from beginning to end on a single, continuous production line. They are employed in the manufacturing of large-molecule and small-molecule therapeutics and assist in the manufacturing of solid formulations, liquid, and semi-solid formulations. They are used in applications such as final drug product manufacturing and active pharmaceutical ingredient (API) manufacturing and are utilized by various end-users such as pharmaceutical companies, contract manufacturing organizations, and others.

What Is The Pharmaceutical Continuous Manufacturing Market Growth Forecast?

The pharmaceutical continuous manufacturing market size is expected to see rapid growth in the next few years. It will grow to $4.58 billion in 2030 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to growing adoption of pcm by big pharma, increasing investment in smart factories, demand for faster scale-up and commercialization, focus on supply chain resilience, advancements in continuous processing equipment. Major trends in the forecast period include shift from batch to end-to-end continuous production, increased adoption of modular and flexible manufacturing lines, growing focus on real-time quality assurance and control, expansion of continuous manufacturing for API production, rising regulatory support for continuous manufacturing.

Global Pharmaceutical Continuous Manufacturing Market Segmentation

1) By Product: Integrated Continuous System, Control And Software, Semi-Continuous System 2) By Therapeutics Type: Large Molecule, Small Molecule 3) By Formulation: Solid Formation, Liquid And Semi-Solid Formation 4) By Application: Final Drug Product Manufacturing, Active Pharmaceutical Ingredient (API) Manufacturing 5) By End-Users: Pharmaceutical Companies, Contract Manufacturing Organization, Other End-Users Subsegments: 1) By Integrated Continuous System: Continuous Mixer Systems, Continuous Granulation Systems, Continuous Tablet Press Systems, Continuous Coating Systems 2) By Control and Software: Process Analytical Technology (PAT) Tools, Manufacturing Execution Systems (MES), Control Software for Automation, Data Management and Visualization Software 3) By Semi-Continuous System: Batch-to-Continuous Transition Systems, Hybrid Systems, Semi-Continuous Granulation and Drying Systems

What Is The Driver Of The Pharmaceutical Continuous Manufacturing Market?

The increase in industrial automation is expected to propel the growth of the pharmaceutical continuous manufacturing market going forward. Industrial automation refers to the use of control systems, such as computers or robots, for handling different processes and machinery in an industry to replace or augment human intervention. Industrial automation helps pharmaceutical continuous manufacturing in monitoring and real-time feedback control in CM processes to minimize human error and ensure consistent product quality. For instance, in September 2023, according to the World Robotics report published by the International Federation of Robotics, a Germany-based professional non-profit organization, there were 553,052 industrial robot installations in factories worldwide, marking a 5% year-on-year growth rate in 2022. Therefore, the increase in industrial automation is driving the growth of the pharmaceutical continuous manufacturing industry.

Key Players In The Global Pharmaceutical Continuous Manufacturing Market

Major companies operating in the pharmaceutical continuous manufacturing market are Pfizer Inc., Robert Bosch GmbH, Siemens AG, Novartis AG, Thermo Fisher Scientific Inc., GlaxoSmithKline Plc., Eli Lilly and Company, Corning Inc., Vertex Pharmaceuticals, Lonza Group Ltd., GEA Group AG, Catalent Inc., Mettler Toledo, Patheon, Cytiva, Samsung Biologics Co.Ltd., WuXi Biologics, Syntegon Technology GmbH, Coperion GmbH, Hosokawa Micron Group, FUJIFILM Diosynth Biotechnologies, Leistritz AG, Glatt GmbH, Freund-Vector Corp., SK biotek Co. Ltd., Gericke AG, GEBRÜDER LÖDIGE MASCHINENBAU GmbH, Munson Machinery Company Inc., L.B. Bohle Maschinen und Verfahren GmbH, KORSCH AG, Chemtrix BV

Global Pharmaceutical Continuous Manufacturing Market Trends and Insights

Major companies operating in the pharmaceutical continuous manufacturing market are focusing on the development of advanced equipment, such as continuous manufacturing lines, to gain a competitive edge in the market. A Continuous Manufacturing (CM) line is a specialized production system in which raw materials are seamlessly transformed into finished products without any interruptions or pauses. For instance, in January 2023, WuXi STA, a China-based contract research, development, and manufacturing organization (CRDMO), launched the Continuous Manufacturing (CM) line for oral solids in Wuxi City, China. This CM line, compliant with global cGMP regulations, introduces advancements in oral drug development by incorporating continuous direct compression equipment for dispensing, blending, lubrication, tablet compression, and coating. Notably, Process Analytical Technology (PAT) is integrated to monitor blending uniformity in real-time, ensuring high product quality.

What Are Latest Mergers And Acquisitions In The Pharmaceutical Continuous Manufacturing Market?

In January 2023, Cambrex Corporation, a US-based contract development manufacturing organization (CDMO) for pharmaceuticals, acquired Snapdragon Chemistry Inc. for an undisclosed sum. With this acquisition, Cambrex Corporation strengthened its expertise in active pharmaceutical ingredient (API) process development in continuous flow manufacturing, which would complement recent investments in endless flow process development capabilities. Snapdragon Chemistry Inc. is a US-based contract research, development, and chemical production company specializing in active pharmaceutical ingredient (API) batch and continuous flow process development.

Regional Insights

Western Europe was the largest region in the pharmaceutical continuous manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Pharmaceutical Continuous Manufacturing Market?

The pharmaceutical continuous manufacturing market consists of revenues earned by entities by providing manufacturing services such as mixing, granulation, coating, and tablet compression. The market value includes the value of related goods sold by the service provider or included within the service offering. The pharmaceutical continuous manufacturing market also includes sales of organic PCM and inorganic PCM techniques. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pharmaceutical Continuous Manufacturing Market Report 2026?

The pharmaceutical continuous manufacturing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical continuous manufacturing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.